VAERS reports by lot

GSK DTaP/Tdap lot HB7L7: VAERS reports

56 VAERS reports list lot HB7L7 as a GSK DTaP/Tdap vaccine, received between 2019-08-19 and 2022-10-28. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
56
Reports
2%
Marked serious
0
With a death outcome
21
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Injection-site / Local reaction3656%
Allergic / Anaphylactic1016%
Dermatological (non-injection-site)914%
General / Systemic (non-local)58%
Musculoskeletal23%
Neurological12%
Psychiatric / Neuropsychiatric12%

Where reports came from

U.S. state of the reporter, where given (top 12).

Michigan13
Massachusetts3
Kentucky3
California3
Texas3
Colorado2
Florida2
Washington2
North Carolina2
Kansas2
New York2
Arizona2

Reports by month received

2019-082
2019-095
2019-107
2019-115
2019-122
2020-013
2020-023
2020-031
2020-041
2020-061
2020-071
2020-085
2020-111
2021-044
2021-051
2021-061
2021-071
2021-085
2021-095
2021-101
2022-101

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.